Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a...

por Vehreschild, Maria J. G. T., Taori, Surabhi, Goldenberg, Simon D., Thalhammer, Florian, Bouza, Emilio, van Oene, Joop, Wetherill, Graham, Georgopali, Areti
Publicado 2018

Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepati...

por Vehreschild, Maria J. G. T., Taori, Surabhi, Goldenberg, Simon D., Thalhammer, Florian, Bouza, Emilio, van Oene, Joop, Wetherill, Graham, Georgopali, Areti
Publicado 2018